Why Pfizer Might Be the Most Underrated Dividend Stock to Buy Right Now

Pfizer generated $11 billion in free cash flow over the past four quarters, more than $1 billion above its dividend payments; adjusted EPS in its latest quarter was $0.77 versus a $0.43 quarterly dividend. The article argues the 6.2% yield is supported by cash flow despite recent reported losses, while restructuring and patent cliffs remain risks. Shares are up more than 10% this year but down 35% over five years, and trade at 10 times forward earnings versus a 20 times S&P 500 average; Pfizer has 95 drug candidates in its pipeline.

Analysis

The key question is not whether the current dividend is covered by a recent cash-flow snapshot, but whether cash generation remains durable as patent expirations pressure the revenue base. Adjusted EPS coverage and reported free cash flow are useful checks, not guarantees: working-capital swings, restructuring cash costs, and the investment needed to replace lost products can reduce distributable cash. A high yield therefore may compensate for a real risk of slower growth or a future payout reset, rather than signal mispricing by itself.

The pipeline is an option, not yet a replacement revenue stream. Candidate count says little about probability of approval, launch timing, or commercial scale; near-term earnings may face pressure well before successful launches contribute materially. That creates a potential second-order constraint: if cash generation weakens, Pfizer may have less flexibility to fund R&D, business development, and dividends simultaneously. Competitors such as Merck and Bristol Myers Squibb offer relevant sector context, but their product cycles differ; compare exposure and pipeline progress rather than assuming a simple peer valuation gap.

Near term, the dividend and yield may support the shares, but a durable rerating needs evidence of offsetting product growth and stable cash conversion. Over 1–3 months, watch guidance and cash-flow disclosure; over 6–18 months, monitor whether launches and pipeline milestones replace revenue lost to exclusivity. The bullish case is falsified by sustained deterioration in operating cash flow or dividend coverage, material guidance cuts, or pipeline setbacks without credible replacement growth. The article’s valuation argument is conditional on analyst earnings estimates holding up.

Key Decisions for Investors

• Do not buy solely on the headline yield. Verify the latest full-year free-cash-flow outlook, cash restructuring costs, and dividend coverage against actual cash generation—not adjusted EPS alone.
• For investors seeking turnaround exposure, consider a modest, staged PFE position rather than a full allocation ahead of evidence that new products can offset patent-related declines. Reassess after guidance updates and material clinical or regulatory milestones.
• Track operating cash flow, product-level revenue trends, and pipeline milestones over the next 1–3 months and 6–18 months, respectively. Reduce or avoid the position if cash coverage weakens persistently or guidance implies the replacement-growth gap is widening.
• Treat peer comparisons with Merck and Bristol Myers Squibb as a product-cycle and pipeline screen, not a standalone valuation trade; their patent exposure and growth drivers are not interchangeable.